Premium
Highly sensitive chemiluminescence immunoassay on chitosan membrane modified paper platform using TiO 2 nanoparticles/multiwalled carbon nanotubes as label
Author(s) -
Li Weiping,
Ge Shenguang,
Wang Shoumei,
Yan Mei,
Ge Lei,
Yu Jinghua
Publication year - 2013
Publication title -
luminescence
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.428
H-Index - 45
eISSN - 1522-7243
pISSN - 1522-7235
DOI - 10.1002/bio.2482
Subject(s) - electrochemiluminescence , detection limit , immunoassay , chemiluminescence , carbon nanotube , luminol , analyte , chitosan , materials science , nanoparticle , linear range , chromatography , nanotechnology , nuclear chemistry , chemistry , medicine , organic chemistry , antibody , immunology
A highly sensitive chemiluminescence (CL) immunoassay was incorporated into a low‐cost microfluidic paper‐based analytical device (μ‐PAD) to fabricate a facile paper‐based CL immunodevice (denoted as μ‐PCLI). This μ‐PCLI was constructed by covalently immobilizing capture antibody on a chitosan membrane modified μ‐PADs, which was developed by simple wax printing methodology. TiO 2 nanoparticles coated multiwalled carbon nanotubes (TiO 2 /MWCNTs) were synthesized as an amplification catalyst tag to label signal antibody (Ab 2 ). After sandwich‐type immunoreactions, the TiO 2 /MWCNTs were captured on the surface of μ‐PADs to catalyze the luminol‐ p ‐iodophenol‐H 2 O 2 CL system, which produced an enhanced CL emission. Using prostate‐specific antigen as a model analyte, the approach provided a good linear response range from 0.001 to 20 ng/mL with a low detection limit of 0.8 pg/mL under optimal conditions. This μ‐PCLI showed good reproducibility, selectivity and stability. The assay results of prostate‐specific antigen in clinical serum samples were in good agreement with that obtained by commercially used electrochemiluminescence methods at the Cancer Research Center of Shandong Tumor Hospital (Jinan, Shandong Province, China). This μ‐PCLI could be very useful to realize highly sensitive, qualitative point‐of‐care testing in developing or developed countries. Copyright © 2013 John Wiley & Sons, Ltd.